GE Healthcare has announced that it has received US Food and Drug Administration (FDA) clearance for its Discovery IGS 740, a new rail-free mobile angiography system with a 41x41cm detector. The Discovery IGS 740 is the first of this kind of mobile angiography system in the industry to receive FDA approval.
According to GE Healthcare, the rail-free design of this new imaging system allows healthcare professionals ample access to the patient while freeing clinical teams from the constraints of fixed ceiling-mounted system rails. Its wide bore C-Arm and dedicated arm-imaging positions create ease in imaging the anatomy of interest, and full patient access from the left or right. A rotating laser continuously scans the room so the system knows where it is at all times.
By eliminating the ceiling rails, installation is simplified for flexibility in designing the room and positioning ceiling-mounted ancillaries (monitors, radshields, lights) where healthcare professionals need them.
The Discovery IGS 740 is equipped with two customisable parking positions to accommodate multiple room sizes and shapes. The 41x41cm detector enables imaging of large organs, such as the liver and simultaneous coverage of both legs. The wide-bore C-arm helps interventional radiologists image large patients and conveniently perform off centred 3D acquisitions. In addition, the system comes equipped with more than 20 advanced applications, such as FlightPlan for Liver, which helps clinicians identify tumour-feeding vessels in a few clicks, and be selective during liver embolisations.
“Our goal is to pioneer a solution designed to free interventional radiologists from traditional constraints,” says Chantal Le Chat, general manager of GE Healthcare Premium Angiography. “With the enhanced mobility of the Discovery IGS 740, clinicians have full freedom to operate, and we believe this can revolutionise the field of interventional imaging.”